BASELINE CLINICAL, ENDOCRINE, AND METABOLIC PROFILE OF REPRODUCTIVE-AGED WOMEN WITH POLYCYSTIC OVARY SYNDROME

Abstract

Background:

Polycystic ovary syndrome (PCOS) represents a complex endocrine condition characterized by reproductive dysfunction and metabolic disturbances. Identification of baseline clinical and biochemical features prior to therapeutic intervention is essential for understanding disease heterogeneity and improving individualized treatment strategies.

Objective:

To characterize the clinical manifestations, hormonal profile, and metabolic status of women of reproductive age diagnosed with polycystic ovary syndrome before initiation of any therapeutic measures.

Methods:

A descriptive cross-sectional study was performed in women aged 18–40 years with PCOS diagnosed according to the Rotterdam criteria. Clinical evaluation included assessment of menstrual function, anthropometric parameters, and signs of androgen excess. Endocrine evaluation comprised serum levels of gonadotropins and androgens. Metabolic status was assessed through fasting glucose, insulin concentrations, lipid profile, and insulin resistance indices.

Results:

The majority of participants demonstrated menstrual dysfunction and varying degrees of clinical hyperandrogenism. Hormonal analysis revealed dysregulated gonadotropin secretion, manifested by elevated luteinizing hormone levels and increased LH/FSH ratios, along with elevated androgen concentrations. Metabolic assessment identified insulin resistance and lipid abnormalities in a substantial proportion of patients, including those with normal body mass index.

Conclusion:

Women with PCOS exhibit significant clinical, endocrine, and metabolic abnormalities prior to treatment initiation. Early identification of these baseline features is critical for risk stratification and development of optimized therapeutic approaches.